NewsMeter
Once weekly, taken by mouth: the dosing claim that NextCure and Avere Therapeutics are staking a merger on. Avere's lead asset, AVR-001, is an oral peptide interleukin-23 receptor antagonist.
Phase 1b data in psoriasis, per the companies' joint announcement, supports its potential for rapid development in that indication. The companies describe AVR-001 as differentiated.
No response rate or safety summary from the Phase 1b trial appears in the release.
"Supports its potential to be rapidly developed as a convenient, once-weekly" therapy is the companies' characterization, not an independent data assessment.
Keep reading